Krakowska Akademia Neurologii Sp. z o.o.
- Address
- lock Available on a paid plan
Immune‑Mediated Neurological Disorders
The Centrum Neurologii Klinicznej at Krakowska Akademia Neurologii focuses on immune system diseases that affect the nervous system, especially multiple sclerosis and myasthenia gravis. Researchers are evaluating new biologic agents and complement inhibitors to improve long‑term outcomes for patients.
- Evaluation of anti‑B‑cell therapy in relapsing multiple sclerosis
- Assessment of complement inhibition for generalized myasthenia gravis
- Investigation of FcRn antagonists in AChR‑positive myasthenia gravis
- Long‑term safety of subcutaneous infusion therapy in advanced Parkinson’s disease
With 33 active trials and 15 investigators, the site advances therapeutic options for autoimmune neurological conditions while maintaining a strong safety monitoring program.
Neurodegenerative Movement Disorders
Studies at the center target early and progressive forms of movement disorders, aiming to slow disease progression and enhance motor function in Parkinson’s disease, Huntington’s disease and related conditions.
- Continuous subcutaneous infusion of a dopamine agonist for advanced Parkinson’s disease
- Antibody therapy directed at α‑synuclein in early Parkinson’s disease
- Disease‑modifying antisense treatment for early Huntington’s disease
- CSF huntingtin protein monitoring in prodromal Huntington’s disease
The program emphasizes long‑term safety and efficacy, offering participants access to innovative treatments that may alter disease trajectories.
Cognitive Decline and Dementia
Research efforts address the early stages of Alzheimer’s disease and related cognitive impairments, testing interventions that could preserve memory and reduce neuropsychiatric symptoms.
- Oral semaglutide impact on cognition in Mild Cognitive Impairment
- Intrathecal antisense therapy for early symptomatic Alzheimer’s disease
- Agitation reduction strategies in Alzheimer’s disease dementia
- Clinical rating scale improvements with novel agents in early Alzheimer’s disease
Krakowska Akademia Neurologii supports patients through comprehensive monitoring and provides opportunities to join trials focused on slowing cognitive decline.
Epilepsy and Migraine Management
The site conducts trials to improve seizure control and migraine prevention, evaluating newer formulations and delivery methods for better patient outcomes.
- Extended‑release levetiracetam for drug‑resistant focal onset seizures
- Botulinum toxin injection for upper‑limb spasticity after stroke
- Xeomin® therapy for reducing monthly attacks in chronic migraine
- Xeomin® therapy for reducing monthly attacks in episodic migraine
These studies aim to enhance quality of life by delivering faster, more durable relief for patients living with seizure disorders and migraine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 40 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Novartis Pharma AG3active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG7trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krakowska Akademia Neurologii Sp. z o.o.
lock Showing 1 of 42 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, First-in-Human Study to Evaluate the Safety and Pharmacokinetics of RO7812653 in Patients with Early Symptomatic Alzheimer’s Disease | F. Hoffmann-La Roche AG | Phase I | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 40 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Efgartigimod Alfa | 4 | Unknown | 2024-10-16 | 2026-03-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.